Skip to main content

Pfizer’s COVID revenues have dropped off along with attention to the pandemic

Wall Street urged Pfizer to lower its COVID revenue estimates. The company did — but it's still betting on higher demand for its vaccine and antiviral by 2025.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.